您要查找的是不是：
- Median overall survival of all 211 patients was 49.3 months. 所有211名患者的中位總存活數是49.;3個(gè)月。
- MabThera has revolutionized the treatment of lymphoma and is the first therapy in over 20 years to increase overall survival for aggressive non-Hodgkin's Lymphoma patients. 美羅華 實(shí)現了淋巴瘤治療方面的革命，是20多年來(lái)的首個(gè)能提高侵襲性非霍奇金氏淋巴瘤患者的總存活率的藥物。
- Median TTF was 5.5 months, and median overall survival (OS) was 22.4 months. 中位治療失敗時(shí)間為5.;5個(gè)月，中位生存期22
- BMI and visceral adiposity showed no influence on overall survival of patients. BMI及內臟肥胖對總生存沒(méi)有影響。
- Dr Smith concludes: "Our results indicate that trastuzumab [Herceptin] shows a significant overall survival benefit in early breast cancer over observation alone after chemotherapy. 研究結果表明與單純化療后觀(guān)察比較，應用群司珠單抗[赫賽汀]可使早期乳腺癌患者總生存率明顯提高。
- The five-gene signature was an independent predictor of relapse-free and overall survival. 這五個(gè)基因是對無(wú)復發(fā)和總生存率的獨立預測指標。
- The 3-year overall survival (OS) and disease free survival ( DFS) was 66. 3% and 59. 5% , respectively. 3年總生存率和無(wú)病生存率分別為66.;3%25和59
- The 5 -year overall survival (OS) and disease free survival (DFS) were 89% and 73%,respectively. 全組5年總生存率和無(wú)病生存率分別為89%25和73%25。
- Our five-gene signature is closely associated with relapse-free and overall survival among patients with NSCLC. 我們的五個(gè)基因標記與非小細胞肺癌患者的無(wú)復發(fā)及總生存率密切相關(guān)。
- Nodal status correlates with disease-free and overall survival better than other prognostic factors. 與其他預后因素相比，結節狀況與無(wú)病及總存活率關(guān)系更大。
- A bit of strategic cannibalism boosts overall survival chances for the larvae left "standing" when the music stops. 同類(lèi)相食的策略讓那些在“搶座位”游戲中幸存的幼蟲(chóng)擁有更高的生存幾率。
- Clinical curing rate and the overall survival rate drop with the increasing of the shift rate of lymph nodes. 問(wèn)題：臨床治愈率和整體生存率隨淋巴結轉移率的增加而降低。
- Secondary endpoints for the study include disease-free survival, overall survival, safety, and tolerability. 該研究的次級目標包括無(wú)瘤生存率、總生存率、安全性以及耐受性。
- Primary and secondary endpoints were recurrence-free survival (RFS) and overall survival (OS), respectively. 最初的和輔助的的終點(diǎn)分別是無(wú)復發(fā)生存率和總生存率。
- In conclusion, the response rate and overall survival with docetaxel + cisplatin were greater than that seen with VC. 總之，緩解率及總生存在泰索帝+順鉑組比VC組好，在泰索帝+卡鉑組與對照組相當。
- Overall survival after re-OLT was about 10% to 20% lower than that after primary OLT. 再次移植相對于首次移植生存率低大約10%25至20%25。
- The overall survival curves of the 2 cohorts were superimposable, the researchers commented. 研究者評論說(shuō)，兩組患者總的生存曲線(xiàn)重疊。
- Methods: End points were remission rates [overall response (OR) and complete response (CR)], failure-free survival (FFS), overall survival (OS)and toxicity. 方法臨床觀(guān)察的終點(diǎn)包括緩解率(總有效率OR和完全緩解率CR),無(wú)失敗生存(FFS),總體生存(OS)及毒性。
- The premenopausal patients gave DFSR of 72.8% and 35.7% ( P <0.01), and their overall survival rates were 80.7% and 60.6% ( P < 0.05). 絕經(jīng)前患者的內分泌治療組和化療組 5年無(wú)病生存率分別為 72 8%25和 35 7%25 (P <0 0 1) ;5年總生存率分別為 80 7%25和 6 0 0%25 (P <0 0 5 )。
- The total CR is 62.0% and disease-free survival (DFS) rate and overall survival (OS) rate at five-year are 52.3% and 46.8%,respectively. 全組患者治療后的完全緩解(CR)率為62.;0%25，5年無(wú)病生存率和總生存率分別為52
